Sonic Healthcare (SHL) Stock Price, Fundamentals & Analysis

What SHL does

Sonic Healthcare (SHL) is a stock listed on the ASX that provides medical diagnostic services and administrative support to practitioners across Australia, the United States, Germany, and internationally. The company operates in the Healthcare sector, specifically in Diagnostics & Research, offering laboratory medicine and pathology testing — including biochemistry, genetics, microbiology, and molecular pathology — as well as radiology services such as MRI, CT, ultrasound, and PET CT. It also runs primary care clinics, occupational health services, and chronic disease management programs. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia, employing around 47,000 people.

Key numbers explained

• The current price is 18.79 AUD, down 0.64% today, with a 52-week range of 18.26 – 24.27 and a 12-month price change of -11.5%.
• The trailing P/E ratio of 15.3 shows how much investors pay per dollar of recent earnings; the forward P/E ratio of 14.3 uses expected future earnings.
• The dividend yield of 5.75% indicates the annual dividend as a percentage of the share price, with 88% of earnings paid out as dividends.
• The ex-dividend date is 2 Sept. 2026; the beta of 0.58 suggests the stock tends to be less volatile than the broader market.
• Revenue for the trailing 12 months is 10.87 mld. AUD, growing 8.9% year over year, with a profit margin of 5.6% and an operating margin of 9.7%.
• The debt-to-equity ratio of 68.8% and price-to-book of 1.11 provide a sense of the company's leverage and how its market value compares to its book value.

What to watch

Sonic Healthcare operates in a regulated healthcare environment where policy changes, reimbursement rates, and public health demand can affect volumes and margins. Its international exposure — including the United States and Germany — means currency movements and local regulatory conditions are relevant. As a Diagnostics & Research business, investment in technology and integration of new testing capabilities can influence long-term competitiveness. Investors often compare it with peers such as Telix Pharmaceuticals (TLX), Summerset Group Holdings (SNZ), Sigma Healthcare (SIG), Ryman Healthcare (RYM), Regis Healthcare (REG), Pro Medicus (PME), and Fisher & Paykel Healthcare (FPH) to understand sector positioning. The next earnings report is scheduled for 20 Aug. 2026.